Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (371-380 of 484) with videos related to

Pageof 49
Sort By:
JCI Insight|May 25, 2023
Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in miceFranziska Werner, Estefania Prentki Santos, Konstanze Michel, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Rheumatology (Oxford, England)|June 25, 2022
A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosisJennifer M Franks, Diana M Toledo, Viktor Martyanov, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 3, 2020
Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic SclerosisZeinab Taki, Elena Gostjeva, William Thilly, et al.
Thorax|June 26, 2020
Interaction between the promoter <i>MUC5B</i> polymorphism and mucin expression: is there a difference according to ILD subtype?Carmel J Stock, Caterina Conti, Ángeles Montero-Fernandez, et al.
Rheumatology (Oxford, England)|December 19, 2024
Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Rebecca L Ross, Begoña Caballero-Ruiz, Emily L Clarke, et al.
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
JCI Insight|August 9, 2019
Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarctionSumia A Bageghni, Karen E Hemmings, Nadira Y Yuldasheva, et al.
Respiratory Research|August 7, 2013
Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung diseaseGisela E Lindahl, Carmel Jw Stock, Xu Shi-Wen, et al.
Pageof 49

Showing results (371-380 of 484) with videos related to

Sort By:
Pageof 49
JCI Insight|May 25, 2023
Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in miceFranziska Werner, Estefania Prentki Santos, Konstanze Michel, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
Rheumatology (Oxford, England)|June 25, 2022
A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosisJennifer M Franks, Diana M Toledo, Viktor Martyanov, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 3, 2020
Pathogenic Activation of Mesenchymal Stem Cells Is Induced by the Disease Microenvironment in Systemic SclerosisZeinab Taki, Elena Gostjeva, William Thilly, et al.
Thorax|June 26, 2020
Interaction between the promoter <i>MUC5B</i> polymorphism and mucin expression: is there a difference according to ILD subtype?Carmel J Stock, Caterina Conti, Ángeles Montero-Fernandez, et al.
Rheumatology (Oxford, England)|December 19, 2024
Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS)Rebecca L Ross, Begoña Caballero-Ruiz, Emily L Clarke, et al.
The Lancet. Rheumatology|November 8, 2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux diseaseMichael Hughes, Yannick Allanore, Murray Baron, et al.
JCI Insight|August 9, 2019
Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarctionSumia A Bageghni, Karen E Hemmings, Nadira Y Yuldasheva, et al.
Respiratory Research|August 7, 2013
Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung diseaseGisela E Lindahl, Carmel Jw Stock, Xu Shi-Wen, et al.
Pageof 49